Table 1.
The demographic data of the 50 patients and the 50 HSCTs included in the study.
| Disease | Frequency | Gender F/M | Median age (x–y) | Graft source BM/PB | Conditioning RIC/MAC (seq.) | IS cni/mtor | aGVHD/grades 3–4 | cGVHD yes/no (ne) | Relapse | CMV | Alive 9/2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALL | 6 | 5/1 | 32 (19–66) | 1/5 | 1/5 | 4/2 | 3/0 | 2/3 (1) | 1 | 3 | 5 |
| AML | 23 | 10/13 | 57 (29–68) | 5/18 | 10/8 (5) | 6/16a | 13/6 | 7/12 (4) | 4 | 12 | 15 |
| CLL | 3 | 1/2 | 61 (58–61) | 0/3 | 2/1 | 1/2 | 3/2 | 2/1 | 0 | 1 | 3 |
| MDS | 3 | 1/2 | 60 (58–63) | 1/2 | 2/1 | 1/2 | 1/1 | 2/1 | 0 | 2 | 2 |
| MF | 1 | 1/0 | 51 | 0/1 | 1/0 | 0/1 | 1/1 | (1) | 1 | 1 | 0 |
| MM | 7 | 4/3 | 55 (43–62) | 0/7 | 3/4 | 2/5 | 5/4 | 5/2 | 0 | 5 | 5 |
| MPN | 1 | 0/1 | 43 | 0/1 | 0/1 | 0/1 | 0 | (1) | 1 | 1 | 0 |
| SAA | 3 | 3/0 | 55 (22–63) | 3 | 4/0 | 3/1 | 3/0 | 1/2 | 1 | 1 | 2 |
| MbH | 1 | 0/1 | 43 | 0/1 | 0/1 | 0/1 | 0 | 0/1 | 0 | 0 | 1 |
| NHL | 1 | 0/1 | 24 | 0/1 | 1/0 | 0/1 | 0 | 1/0 | 1 | 0 | 0 |
| T-LBL | 1 | 0/1 | 64 | 0/1 | 0/1 | 0/1 | 1/1 | 1/0 | 1 | 0 | 0 |
| Total | 50 | 25/25 | 55 (19–68) | 10/40 | 24/21 (5) | 17/33 | 30/15 | 21/22 (7) | 9 | 26 | 33 |
Patient hematological malignancies varied a lot. Primary diseases were acute myelogenous (AML) and lymphoblastic leukemia (ALL), chronic lymphoblastic (CML) and myelomonocytic (MM) leukemia, myelodysblastic syndrome (MDS), myelofibrosis (MF), myeloproliferative neoplasms (MPN), severe aplastic anemia (SAA), Hodgkin (MbH) and non-Hodgkin lymphomas (NHL), and T-cell lymphoblastic lymphoma (T-LBL).
ne, not evaluable.
aOne patient received steroid treatment.